105
Views
5
CrossRef citations to date
0
Altmetric
Original Article

MEC (Mitoxantrone, Etoposide and Intermediate Dose Cytarabine): An Effective Induction Regimen for Previously Untreated Acute Non-Lymphocytic Leukemia

, , , , , , , , & show all
Pages 447-451 | Received 21 Jan 1995, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Maurizio Miglino, Nicoletta Colombo, Gianmatteo Pica, Raffaella Grasso, Marino Clavio, Micaela Bergamaschi, Filippo Ballerini, Anna Ghiso, Chiara Ghiggi, Laura Mitscheunig, Germana Beltrami, Antonia Cagnetta, Luana Vignolo, Maria Vita Lucchetti, Sara Aquino, Ivana Pierri, Mario Sessarego, Angelo Michele Carella & Marco Gobbi. (2011) WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leukemia & Lymphoma 52:10, pages 1961-1969.
Read now

Articles from other publishers (4)

Kaito Harada, Noritaka Sekiya, Shuntaro Ikegawa, Shugo Sasaki, Takeshi Kobayashi & Kazuteru Ohashi. (2018) Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia. International Journal of Hematology 109:2, pages 233-238.
Crossref
J. Aubrey Waddell & Dominic A. SolimandoJr.Jr.. (2017) Mitoxantrone, Etoposide, and Cytarabine (MEC) Regimen for Relapsed or Refractory Acute Myelogenous Leukemia. Hospital Pharmacy 38:3, pages 218-221.
Crossref
Silvia BuonamiciEmanuela OttavianiNicoletta TestoniVittorio MontefuscoGiuseppe VisaniFrancesca BonifaziMarilina AmabileCarolina TerragnaDeborah RuggeriPier Paolo PiccalugaAlessandro IsidoriMichele MalagolaMichele BaccaraniSante TuraGiovanni Martinelli. (2002) Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 99:2, pages 443-449.
Crossref
G Visani, D Milligan, F Leoni, J Chang, S Kelsey, R Marcus, R Powles, S Schey, A Covelli, A Isidori, M Litchman, PP Piccaluga, H Mayer, M Malagola & C Pfister. (2001) Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia 15:5, pages 764-771.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.